• Je něco špatně v tomto záznamu ?

Multiple sclerosis and COVID-19

J. Mares, H. P. Hartung

. 2020 ; 164 (3) : 217-225. [pub] 20200717

Jazyk angličtina Země Česko

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc21021182

This paper reviews currently available data on the novel coronavirus and clinical features of COVID-19, followed by a detailed section on possible modifications of immunomodulatory therapy in multiple sclerosis patients with COVID-19, based on what we know so far. There are discussed: (i) The COVID-19 disease (Epidemiological background SARS-CoV-1 coronavirus; Autoimmune response to COVID-19; Asymptomatic course; SARS-CoV-2 test; COVID-19 symptoms), (ii) Treatment of COVID-19 (Experimental plasma treatment; Antiviral therapy; Antimalarial treatment scheme; Biological treatment; Corticosteroid treatment; Symptomatic treatment; Vaccine preparation) and (iii) Multiple sclerosis and SARS-CoV-2 infection (Epidemiological recommendation).

Citace poskytuje Crossref.org

Bibliografie atd.

Literatura

000      
00000naa a2200000 a 4500
001      
bmc21021182
003      
CZ-PrNML
005      
20210908164858.0
007      
ta
008      
210806s2020 xr d f 000 0|eng||
009      
AR
024    7_
$a 10.5507/bp.2020.033 $2 doi
035    __
$a (PubMed)32686774
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Mareš, Jan $7 xx0060341 $u Department of Neurology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Czech Republic
245    10
$a Multiple sclerosis and COVID-19 / $c J. Mares, H. P. Hartung
504    __
$a Literatura
520    9_
$a This paper reviews currently available data on the novel coronavirus and clinical features of COVID-19, followed by a detailed section on possible modifications of immunomodulatory therapy in multiple sclerosis patients with COVID-19, based on what we know so far. There are discussed: (i) The COVID-19 disease (Epidemiological background SARS-CoV-1 coronavirus; Autoimmune response to COVID-19; Asymptomatic course; SARS-CoV-2 test; COVID-19 symptoms), (ii) Treatment of COVID-19 (Experimental plasma treatment; Antiviral therapy; Antimalarial treatment scheme; Biological treatment; Corticosteroid treatment; Symptomatic treatment; Vaccine preparation) and (iii) Multiple sclerosis and SARS-CoV-2 infection (Epidemiological recommendation).
650    _2
$a asymptomatické nemoci $x epidemiologie $7 D058070
650    _2
$a autoimunita $7 D015551
650    _2
$a Betacoronavirus $x fyziologie $7 D000073640
650    _2
$a COVID-19 $7 D000086382
650    12
$a koronavirové infekce $x epidemiologie $x imunologie $x terapie $x virologie $7 D018352
650    _2
$a lidé $7 D006801
650    _2
$a imunologické faktory $x farmakologie $7 D007155
650    _2
$a imunomodulace $x imunologie $7 D056747
650    12
$a roztroušená skleróza $x epidemiologie $x imunologie $x terapie $7 D009103
650    12
$a pandemie $7 D058873
650    12
$a virová pneumonie $x epidemiologie $x imunologie $x terapie $x virologie $7 D011024
650    _2
$a SARS-CoV-2 $7 D000086402
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Hartung, Hans-Peter $u Klinik fuer Neurologie, Heinrich-Heine Universitaet Duesseldorf, Germany
773    0_
$w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia $x 1213-8118 $g Roč. 164, č. 3 (2020), s. 217-225
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32686774 $y Pubmed
910    __
$a ABA008 $b A 1502 $c 958 $y p $z 0
990    __
$a 20210806 $b ABA008
991    __
$a 20210907133846 $b ABA008
999    __
$a ok $b bmc $g 1694789 $s 1141635
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 164 $c 3 $d 217-225 $e 20200717 $i 1213-8118 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606
LZP    __
$b NLK118 $a Pubmed-20210806

Najít záznam

Citační ukazatele

Možnosti archivace